Page 9 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

Fixed-dose SC combination of trastuzumab and pertuzumab requires :
39
NO reconstitution  NO dilution  NO weight adjustments

NO IV loading dose  NO port access with a SC injection

Patients currently receiving IV PERJETA + trastuzumab can be transitioned
®
to fixed-dose SC combination of trastuzumab and pertuzumab if eligible. 39

®
*Refers to actual injection time of fixed-dose SC combination of trastuzumab and pertuzumab vs infusion time of IV PERJETA +
trastuzumab and does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
PERJETA and trastuzumab can be given in any order. Please see the PERJETA full Prescribing Information for additional dosing
®
®
information for PERJETA + trastuzumab.
®
The same treatment schedule you are used to with PERJETA +
®
trastuzumab-based therapy
In eBC
 Eligible patients should receive fixed-dose SC combination of trastuzumab and

pertuzumab as part of a complete treatment regimen, every 3 weeks for a total
of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity,
whichever occurs first † 35,39

In mBC
 Eligible patients should receive fixed-dose SC combination of trastuzumab and

pertuzumab alongside docetaxel as first-line treatment, every 3 weeks until
disease progression or unmanageable toxicity, whichever occurs first. 35,39

 The same treatment schedule you are used to with PERJETA + trastuzumab-
®
based therapy. 35,39

† In eBC, patients who begin fixed-dose SC combination of trastuzumab and pertuzumab in the neoadjuvant setting should
receive 3-6 cycles before surgery and should continue treatment after surgery, every 3 weeks, to complete 1 year (up to 18 cycles).
Patients who begin treatment in the adjuvant setting should receive a total of 1 year (up to 18 cycles) of fixed-dose SC
combination of trastuzumab and pertuzumab, every 3 weeks, starting on Day 1 of the first taxane-containing cycle.

M-AE-00000086 9